



1 February 2017

Byotrol plc

("Byotrol" or the "Company")

Board changes and issue of options

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that John Langlands has been appointed as Chairman with effect from today's date and that Nicholas Martel has stepped down as Chairman and as a Director, also with effect today. Nicholas will remain with the Company for a further three months to ensure an orderly hand-over.

John Langlands has considerable business, commercial and City experience having worked for a number of listed companies. He has been CEO since 2003 of British Polythene Industries Plc, a leading European producer of polythene films for packaging and agriculture. BPI was sold to RPC GROUP Plc in August 2016 and John left BPI at the end of January 2017 following the successful integration of BPI into RPC.

Mr. Langlands is also being awarded options over 2,700,000 ordinary shares of 0.25p each ("Options" and "Ordinary Shares") as part of the Company's Unapproved Share Option Scheme (the "Award"). The Options have an exercise price of 4.125p, being the closing mid-market share price on 31 January 2017, vest immediately and expire on 14 October 2021. Following the Award there are now 33,757,500 options over Ordinary Shares representing 12.59 per cent. of the existing issued share capital of the Company.

Mr Langlands holds 300,000 ordinary shares in Byotrol, representing 0.1% of the Company's issued share capital.

Nicholas Martel comments:

"After three enjoyable years as Chairman, I look forward to resuming my previous role of supportive shareholder. I am delighted that John has been appointed as my successor and that he will be leading the next phase of Byotrol as we commercialise our new technologies. With a strong team in place and with the recent progress on our three key projects, Byotrol is well positioned for further growth. John knows Byotrol well already and brings a wealth of relevant business experience across many countries and industries."

David Traynor, Chief Executive, comments:

"We are very grateful to Nicholas for his calm and steady oversight of Byotrol over four years as a NED, three of which as Chairman. We will all miss his insight and support.

The Byotrol team is very much looking forward to working with John. He has first-class industry expertise, City experience and all-round business acumen, including in M&A. We are really pleased to welcome him to our Board."

The following further details are given in accordance with Rule 17 and Schedule 2 (g) of the AIM Rules for Companies:

John Thomson Langlands (age 64)

Current directorships or partnerships: Maven Capital (Telfer House) LLP

Previous directorships or partnerships in the past 5 years:

British Polythene Industries Limited (formerly British Polythene Industries PLC)

British Polythene Limited

BPI Limited

Scott and Robertson Limited

BPI Employees trust Limited

Flexfilm Limited

Jordan Plastics Limited

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Enquiries:

Byotrol plc 01925 742 000
David Traynor – Chief Executive

finnCap Ltd 020 7220 0500
(Nominated Adviser & Broker)
Geoff Nash/Carl Holmes/James Thompson - Corporate Finance
Mia Gardner - Corporate Broking

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist in developing, formulating and commercialising cutting-edge antimicrobial technologies.

Our patented suite of technologies delivers powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives. For more information, please go to www.byotrol.com